# First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100

> **NCT05426746** · PHASE1 · COMPLETED · sponsor: **Aqualung Therapeutics Corp.** · enrollment: 32 (actual)

## Conditions studied

- ARDS, Human

## Interventions

- **DRUG:** ALT-100
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT05426746
- **Lead sponsor:** Aqualung Therapeutics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-05
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-05-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05426746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05426746, "First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05426746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*